The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Freeman, E. W.
* Articles by Sondheimer, S. J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Freeman, E. W.
* Articles by Sondheimer, S. J.

Am J Psychiatry 1992; 149:531-533
Copyright © 1992 by American Psychiatric Association


BRIEF REPORTS

Course of premenstrual syndrome symptom severity after treatment

EW Freeman, K Rickels and SJ Sondheimer
Department of Obstetrics/Gynecology, School of Medicine, University of Pennsylvania, Philadelphia 19104.

OBJECTIVE: Patients from a randomized, double-blind, placebo-controlled study of progesterone suppository treatment for premenstrual syndrome (PMS) were followed up to determine poststudy PMS symptom levels and medication use. METHOD: An average of 1 year after the end of the treatment study, 129 subjects were contacted for telephone interviews. All subjects met criteria for PMS before the progesterone suppository treatment, and their symptoms were confirmed by daily symptom reports throughout the study. The outcome measure at follow-up was the patient's global assessment of symptom severity, which was also rated by the subjects during the treatment study. The ratings at enrollment, end of study, and follow-up were compared. RESULTS: Only 27% of the subjects (N = 35) were taking medications for PMS at follow-up. Symptom severity at follow-up was less than at enrollment but greater than at the end of the study. CONCLUSIONS: Some of the improvement gained during treatment was maintained, but overall the subjects remained moderately symptomatic. Validation of the PMS condition, education, and support and caring may account for the symptom decreases during treatment, and the end of treatment and withdrawal of these conditions may account for the moderate return of symptoms.


This article has been cited by other articles:


Home page
NEJMHome page
M. Steiner, S. Steinberg, D. Stewart, D. Carter, C. Berger, R. Reid, D. Grover, D. Streiner, and The Canadian Fluoxetine/Premenstrual Dysphoria Col
Fluoxetine in the Treatment of Premenstrual Dysphoria
N. Engl. J. Med., June 8, 1995; 332(23): 1529 - 1534.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1992 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org